Summary

India Vaccine Market Size & Trends

The India vaccine market was estimated at USD 2.45 billion in 2024 and is projected to reach USD 5.20 billion by 2033, growing at a CAGR of 8.50% from 2025 to 2033. This growth is driven by a high burden of infectious diseases, including tuberculosis, hepatitis, pneumonia, and influenza, highlighting the need for effective vaccination programs. For instance, in June 2025, the World Health Organization reported that approximately 29.8 million individuals in India were living with HBV infection in 2022, which was the third leading cause of cirrhosis and accounted for around 98,305 deaths.

Chronic HBV increased the risk of hepatocellular carcinoma, with 25% developing HCC, and reactivation triggering acute-on-chronic liver failure. Rising awareness and new infectious threats have increased vaccine demand, supporting market expansion.

Advancements in vaccine technology and manufacturing have fueled market expansion in India. Indigenous vaccines such as HPV and COVID-19 have improved self-reliance in production. In June 2025, the Serum Institute of India (SII) became the first vaccine manufacturer worldwide to submit a Prequalification Dossier to the WHO in the electronic Common Technical Document format via the ePQS portal, marking a step forward in regulatory innovation. In 2023, India launched its first indigenous HPV vaccine, Cervavac, developed through collaboration between SII, the Department of Biotechnology, BIRAC, and the Bill & Melinda Gates Foundation. Modern manufacturing methods, facility expansions, and global partnerships have boosted domestic and international supply. These advances, supported by cost-effective production, strengthen India’s leading global vaccine producer position.

The growth of healthcare infrastructure and better access to medical services have supported the expansion of the vaccine market in India. New facilities in underserved regions have improved vaccination delivery. For instance, in March 2025, the Health and Family Welfare Department, Government of Tamil Nadu reported that Tamil Nadu extended immunization services to 4,848 rural health and wellness centres and 500 urban centres.

Daily vaccination sessions were held in hospitals and health centres, while village health nurses conducted outreach at anganwadis and public locations every Wednesday. Free, high-quality vaccines were made more accessible, reducing out-of-pocket costs for families. Secure cold-chain management ensured safe redistribution of unused doses. Alongside mobile units, digital tracking, and strong distribution networks, these efforts have increased vaccine coverage and driven long-term market growth.

The resurgence of seasonal influenza A (H1N1) in India, with over 20,000 reported cases and 347 deaths as of June 2025, underscores a pressing public health challenge. High-risk groups, including the elderly, children, and individuals with chronic conditions, have been particularly affected, leading to increased hospitalizations and outpatient visits. Health authorities are emphasizing robust vaccination strategies, including potential integration of influenza vaccines into the national immunization schedule. Strengthened surveillance and awareness campaigns are essential to reduce transmission, protect vulnerable populations, and enhance healthcare preparedness.

Currently, influenza vaccination coverage in India is only around 1.5%, revealing a significant gap in preventive care. This scenario presents a substantial growth opportunity for the India vaccine industry, driving manufacturers to scale production and distribution. Targeted vaccination drives and public awareness campaigns can improve uptake, while investment in new formulations and combination vaccines could enhance effectiveness. Rising demand will stimulate competition, innovation, and pricing strategies, ultimately strengthening the vaccine ecosystem and supporting public health outcomes in the country.

India Vaccine Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the India vaccine market report based on indication, type, route of administration, age group, and distribution channel:

• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
• Viral Vaccines
o Hepatitis
o Pediatric (Children)
o Adult
o Influenza
o Pediatric (Children)
o Adult
o HPV
o Pediatric (Children)
o Adult
o MMR
o Pediatric (Children)
o Adult
o Rotavirus
o Pediatric (Children)
o Adult
o Herpes Zoster
o Pediatric (Children)
o Adult
o Japanese Encephalitis
o Pediatric (Children)
o Adult
o RSV
o Pediatric (Children)
o Adult
o Others
o Pediatric (Children)
o Adult
• Bacterial Vaccines
o Meningococcal Diseases
o Pediatric (Children)
o Adult
o Pneumococcal diseases
o DPT
o Others Bacterial Vaccines
• Cancer Vaccines
o Pediatric (Children)
o Adult
• Allergy Vaccines
o Pediatric (Children)
o Adult
• Other Indication
o Pediatric (Children)
o Adult
• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Subunit Vaccines
o Recombinant Vaccines
o Conjugate Vaccines
o Toxoid Vaccines
• Inactivated
• Live Attenuated
• mRNA Vaccines
• Viral Vector Vaccines
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Oral
• Parenteral
• Nasal
• Age Group Outlook (Revenue, USD Billion, 2021 - 2033)
• Pediatric Age Group
• Adult Age Group
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital & Retail Pharmacies
• Government Suppliers
• Others Distribution Channel

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Type
1.2.3. Route of Administration
1.2.4. Age Group
1.2.5. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Source
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Source
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. India Vaccine Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. India Vaccine Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2033
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
4.4. Viral Vaccines
4.4.1. Viral Vaccines Market, 2021 - 2033 (USD Billion)
4.4.2. Hepatitis
4.4.2.1. Hepatitis Market, 2021 - 2033 (USD Billion)
4.4.2.2. Pediatric (Children)
4.4.2.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.2.3. Adult
4.4.2.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.4.3. Influenza
4.4.3.1. Influenza Market, 2021 - 2033 (USD Billion)
4.4.3.2. Pediatric (Children)
4.4.3.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.3.3. Adult
4.4.3.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.4.4. HPV
4.4.4.1. HPV Market, 2021 - 2033 (USD Billion)
4.4.4.2. Pediatric (Children)
4.4.4.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.4.3. Adult
4.4.4.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.4.5. MMR
4.4.5.1. MMR Market, 2021 - 2033 (USD Billion)
4.4.5.2. Pediatric (Children)
4.4.5.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.5.3. Adult
4.4.5.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.4.6. Rotavirus
4.4.6.1. Rotavirus Market, 2021 - 2033 (USD Billion)
4.4.6.2. Pediatric (Children)
4.4.6.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.6.3. Adult
4.4.6.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.4.7. Herpes Zoster
4.4.7.1. Herpes Zoster Market, 2021 - 2033 (USD Billion)
4.4.7.2. Pediatric (Children)
4.4.7.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.7.3. Adult
4.4.7.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.4.8. Japanese Encephalitis
4.4.8.1. Japanese Encephalitis Market, 2021 - 2033 (USD Billion)
4.4.8.2. Pediatric (Children)
4.4.8.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.8.3. Adult
4.4.8.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.4.9. RSV
4.4.9.1. RSV Market, 2021 - 2033 (USD Billion)
4.4.9.2. Pediatric (Children)
4.4.9.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.9.3. Adult
4.4.9.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.4.10. Others Viral Vaccines
4.4.10.1. Others Viral Vaccines Market, 2021 - 2033 (USD Billion)
4.4.10.2. Pediatric (Children)
4.4.10.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.4.10.3. Adult
4.4.10.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.5. Bacterial Vaccines
4.5.1. Bacterial Vaccines Market, 2021 - 2033 (USD Billion)
4.5.2. Meningococcal Diseases
4.5.2.1. Meningococcal Diseases Market, 2021 - 2033 (USD Billion)
4.5.2.2. Pediatric (Children)
4.5.2.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.5.2.3. Adult
4.5.2.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.5.3. Pneumococcal diseases
4.5.3.1. Pneumococcal diseases Market, 2021 - 2033 (USD Billion)
4.5.3.2. Pediatric (Children)
4.5.3.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.5.3.3. Adult
4.5.3.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.5.4. DPT
4.5.4.1. DPT Market, 2021 - 2033 (USD Billion)
4.5.4.2. Pediatric (Children)
4.5.4.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.5.4.3. Adult
4.5.4.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.5.5. Others Bacterial Vaccines
4.5.5.1. Others Bacterial Vaccines Market, 2021 - 2033 (USD Billion)
4.5.5.2. Pediatric (Children)
4.5.5.2.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.5.5.3. Adult
4.5.5.3.1. Adult Market, 2021 - 2033 (USD Billion)
4.6. Cancer Vaccines
4.6.1. Cancer Vaccines Market, 2021 - 2033 (USD Billion)
4.6.1.1. Pediatric (Children)
4.6.1.1.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.6.1.2. Adult
4.6.1.2.1. Adult Market, 2021 - 2033 (USD Billion)
4.7. Allergy Vaccines
4.7.1. Allergy Vaccines Market, 2021 - 2033 (USD Billion)
4.7.1.1. Pediatric (Children)
4.7.1.1.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.7.1.2. Adult
4.7.1.2.1. Adult Market, 2021 - 2033 (USD Billion)
4.8. Other Indication
4.8.1. Other Indication Market, 2021 - 2033 (USD Billion)
4.8.1.1. Pediatric (Children)
4.8.1.1.1. Pediatric (Children) Market, 2021 - 2033 (USD Billion)
4.8.1.2. Adult
4.8.1.2.1. Adult Market, 2021 - 2033 (USD Billion)
Chapter 5. India Vaccine Market: Type Business Analysis
5.1. Type Market Share, 2024 & 2033
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
5.4. Subunit Vaccines
5.4.1. Subunit Vaccines Market, 2021 - 2033 (USD Billion)
5.4.1.1. Recombinant Vaccines
5.4.1.1.1. Recombinant Vaccines Market, 2021 - 2033 (USD Billion)
5.4.1.2. Conjugate Vaccines
5.4.1.2.1. Conjugate Vaccines Market, 2021 - 2033 (USD Billion)
5.4.1.3. Toxoid Vaccines
5.4.1.3.1. Toxoid Vaccines Market, 2021 - 2033 (USD Billion)
5.5. Inactivated
5.5.1. Inactivated Market, 2021 - 2033 (USD Billion)
5.6. Live Attenuated
5.6.1. Live Attenuated Market, 2021 - 2033 (USD Billion)
5.7. mRNA Vaccines
5.7.1. mRNA Vaccines Market, 2021 - 2033 (USD Billion)
5.8. Viral Vector Vaccines
5.8.1. Viral Vector Vaccines Market, 2021 - 2033 (USD Billion)
Chapter 6. India Vaccine Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2033
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
6.4. Oral
6.4.1. Oral Market, 2021 - 2033 (USD Billion)
6.5. Parenteral
6.5.1. Parenteral Market, 2021 - 2033 (USD Billion)
6.6. Nasal
6.6.1. Nasal Market, 2021 - 2033 (USD Billion)
Chapter 7. India Vaccine Market: Age Group Business Analysis
7.1. Age Group Market Share, 2024 & 2033
7.2. Age Group Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Billion)
7.4. Pediatric Age Group
7.4.1. Pediatric Age Group Market, 2021 - 2033 (USD Billion)
7.5. Adult Age Group
7.5.1. Adult Age Group Market, 2021 - 2033 (USD Billion)
Chapter 8. India Vaccine Market: Distribution Channel Business Analysis
8.1. Distribution Channel Market Share, 2024 & 2033
8.2. Distribution Channel Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
8.4. Hospital & Retail Pharmacies
8.4.1. Hospital & Retail Pharmacies Market, 2021 - 2033 (USD Billion)
8.5. Government Suppliers
8.5.1. Government Suppliers Market, 2021 - 2033 (USD Billion)
8.6. Others
8.6.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Moderna Inc
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. BioNTech SE ADR
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. CSL Ltd
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Sinovac Biotech Ltd
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. AstraZeneca PLC
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Serum Institute of India Pvt. Ltd.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. GSK PLC
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Merck & Co Inc
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives

ページTOPに戻る

List of Tables/Graphs

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 India vaccine market, by Indication, 2021 - 2033 (USD Billion)
Table 4 India vaccine market, by Type, 2021 - 2033 (USD Billion)
Table 5 India vaccine market, by Route of Administration, 2021 - 2033 (USD Billion)
Table 6 India vaccine market, by Age Group, 2021 - 2033 (USD Billion)
Table 7 India vaccine market, by Distribution Channel, 2021 - 2033 (USD Billion)List of Figures

Fig. 1 India vaccine market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape
Fig. 10 India vaccine market dynamics
Fig. 11 India vaccine market: Porter’s five forces analysis
Fig. 12 India vaccine market: PESTLE analysis
Fig. 13 Indication market, 2021 - 2033 (USD Billion)
Fig. 14 Viral Vaccines market, 2021 - 2033 (USD Billion)
Fig. 15 Hepatitis market, 2021 - 2033 (USD Billion)
Fig. 16 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 17 Adult market, 2021 - 2033 (USD Billion)
Fig. 18 Influenza market, 2021 - 2033 (USD Billion)
Fig. 19 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 20 Adult market, 2021 - 2033 (USD Billion)
Fig. 21 HPV market, 2021 - 2033 (USD Billion)
Fig. 22 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 23 Adult market, 2021 - 2033 (USD Billion)
Fig. 24 MMR market, 2021 - 2033 (USD Billion)
Fig. 25 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 26 Adult market, 2021 - 2033 (USD Billion)
Fig. 27 Rotavirus market, 2021 - 2033 (USD Billion)
Fig. 28 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 29 Adult market, 2021 - 2033 (USD Billion)
Fig. 30 Herpes Zoster market, 2021 - 2033 (USD Billion)
Fig. 31 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 32 Adult market, 2021 - 2033 (USD Billion)
Fig. 33 Japanese Encephalitis market, 2021 - 2033 (USD Billion)
Fig. 34 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 35 Adult market, 2021 - 2033 (USD Billion)
Fig. 36 RSV market, 2021 - 2033 (USD Billion)
Fig. 37 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 38 Adult market, 2021 - 2033 (USD Billion)
Fig. 39 Others Viral Vaccines market, 2021 - 2033 (USD Billion)
Fig. 40 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 41 Adult market, 2021 - 2033 (USD Billion)
Fig. 42 Bacterial Vaccines market, 2021 - 2033 (USD Billion)
Fig. 43 Meningococcal Diseases market, 2021 - 2033 (USD Billion)
Fig. 44 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 45 Adult market, 2021 - 2033 (USD Billion)
Fig. 46 Pneumococcal diseases market, 2021 - 2033 (USD Billion)
Fig. 47 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 48 Adult market, 2021 - 2033 (USD Billion)
Fig. 49 DPT market, 2021 - 2033 (USD Billion)
Fig. 50 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 51 Adult market, 2021 - 2033 (USD Billion)
Fig. 52 Others Bacterial Vaccines market, 2021 - 2033 (USD Billion)
Fig. 53 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 54 Adult market, 2021 - 2033 (USD Billion)
Fig. 55 Cancer Vaccines market, 2021 - 2033 (USD Billion)
Fig. 56 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 57 Adult market, 2021 - 2033 (USD Billion)
Fig. 58 Allergy Vaccines market, 2021 - 2033 (USD Billion)
Fig. 59 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 60 Adult market, 2021 - 2033 (USD Billion)
Fig. 61 Other Indication market, 2021 - 2033 (USD Billion)
Fig. 62 Pediatric (Children) market, 2021 - 2033 (USD Billion)
Fig. 63 Adult market, 2021 - 2033 (USD Billion)
Fig. 64 Type market, 2021 - 2033 (USD Billion)
Fig. 65 Subunit Vaccines market, 2021 - 2033 (USD Billion)
Fig. 66 Recombinant Vaccines market, 2021 - 2033 (USD Billion)
Fig. 67 Conjugate Vaccines market, 2021 - 2033 (USD Billion)
Fig. 68 Toxoid Vaccines market, 2021 - 2033 (USD Billion)
Fig. 69 Inactivated market, 2021 - 2033 (USD Billion)
Fig. 70 Live Attenuated market, 2021 - 2033 (USD Billion)
Fig. 71 mRNA Vaccines market, 2021 - 2033 (USD Billion)
Fig. 72 Viral Vector Vaccines market, 2021 - 2033 (USD Billion)
Fig. 73 Route of Administration market, 2021 - 2033 (USD Billion)
Fig. 74 Oral market, 2021 - 2033 (USD Billion)
Fig. 75 Parenteral market, 2021 - 2033 (USD Billion)
Fig. 76 Nasal market, 2021 - 2033 (USD Billion)
Fig. 77 Age Group market, 2021 - 2033 (USD Billion)
Fig. 78 Pediatric Age Group market, 2021 - 2033 (USD Billion)
Fig. 79 Adult Age Group market, 2021 - 2033 (USD Billion)
Fig. 80 Distribution Channel market, 2021 - 2033 (USD Billion)
Fig. 81 Hospital & Retail Pharmacies market, 2021 - 2033 (USD Billion)
Fig. 82 Government Suppliers market, 2021 - 2033 (USD Billion)
Fig. 83 Others Distribution Channel market, 2021 - 2033 (USD Billion)